149 related articles for article (PubMed ID: 33718174)
1. Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy.
Nakamura Y; Nakayama M; Nishimura B; Okiyama N; Tanaka R; Ishitsuka Y; Matsumoto S; Fujisawa Y
Front Oncol; 2021; 11():618201. PubMed ID: 33718174
[TBL] [Abstract][Full Text] [Related]
2. Complete Response to Nivolumab of Resected Adenocarcinoma NOS With Parotid Gland Origin and Lung Metastasis.
Negishi Y; Okamoto I; Ueda Y; Sato H; Tanigawa M; Nagao T; Tsukahara K
In Vivo; 2022; 36(6):2840-2843. PubMed ID: 36309400
[TBL] [Abstract][Full Text] [Related]
3. Cystadenocarcinoma of the salivary glands with potential lymph node metastasis.
Mukaigawa T; Hayashi R; Miyazaki M; Shinozaki T; Tomioka T; Fujii S
Auris Nasus Larynx; 2016 Jun; 43(3):340-4. PubMed ID: 26441367
[TBL] [Abstract][Full Text] [Related]
4. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney.
Watanabe K; Sugiyama T; Otsuka A; Miyake H
Int Cancer Conf J; 2020 Jan; 9(1):32-35. PubMed ID: 31950015
[TBL] [Abstract][Full Text] [Related]
5. Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy.
Yoshida S; Fujimura T; Kambayashi Y; Amagai R; Hashimoto A; Aiba S
Case Rep Oncol; 2019; 12(3):829-833. PubMed ID: 31762756
[TBL] [Abstract][Full Text] [Related]
6. Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection.
Fujimura T; Kambayashi Y; Sato Y; Tanita K; Amagai R; Hashimoto A; Hidaka T; Aiba S
Front Med (Lausanne); 2019; 6():140. PubMed ID: 31297373
[TBL] [Abstract][Full Text] [Related]
7. Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.
Gambichler T; Strutzmann S; Tannapfel A; Susok L
BMC Cancer; 2017 May; 17(1):327. PubMed ID: 28499411
[TBL] [Abstract][Full Text] [Related]
8. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
9. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
11. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
12. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
13. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
[TBL] [Abstract][Full Text] [Related]
14. Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab.
Okada T; Hamamoto S; Etani T; Naiki T; Sue Y; Banno R; Yamada K; Sakakura T; Yasui T
Int Cancer Conf J; 2020 Apr; 9(2):88-91. PubMed ID: 32257760
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
Finger PT; Pavlick AC
J Immunother Cancer; 2019 Mar; 7(1):83. PubMed ID: 30909967
[TBL] [Abstract][Full Text] [Related]
17. A Rare Distant Metastasis of Papillary Cystadenocarcinoma Arising from Maxillary Gingiva.
Nishimaki F; Gibo T; Tsukada K; Noguchi T; Fukushima T; Kobayashi T; Sekiguchi N; Ozawa T; Koizumi T
Case Rep Oncol; 2020; 13(2):683-688. PubMed ID: 32774257
[TBL] [Abstract][Full Text] [Related]
18. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
19. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
20. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.
Regan MM; Werner L; Rao S; Gupte-Singh K; Hodi FS; Kirkwood JM; Kluger HM; Larkin J; Postow MA; Ritchings C; Sznol M; Tarhini AA; Wolchok JD; Atkins MB; McDermott DF
J Clin Oncol; 2019 Dec; 37(35):3350-3358. PubMed ID: 31498030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
